Perspective Therapeutics reports updated Phase 1/2a data for [212Pb]VMT-α-NET in NETs at ASCO 2025

Perspective Therapeutics, Inc.

No dose-limiting toxicities, no discontinuations due to AEs, and no Grade 4/5 TEAEs in 42 treated patients.
Four of seven patients in Cohort 2 had objective responses per RECIST v1.1; three confirmed, one pending confirmation.
Seven of nine patients from Cohorts 1 and 2 remained progression-free after more than one year of follow-up.
Safety acceptable: low-grade hematologic toxicities; all creatinine increases Grade 1; no serious renal complications.
Cohort 2 re-opened in Aug 2024; 33 additional patients enrolled; company engaging FDA for further dose finding.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.